Planned Solutions Inc. Purchases Shares of 234 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Planned Solutions Inc. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, HoldingsChannel reports. The firm acquired 234 shares of the biopharmaceutical company’s stock, valued at approximately $206,000.

Other hedge funds have also made changes to their positions in the company. Meyer Handelman Co. grew its stake in Regeneron Pharmaceuticals by 11.4% during the 3rd quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock worth $3,485,000 after buying an additional 435 shares during the last quarter. Stifel Financial Corp grew its stake in shares of Regeneron Pharmaceuticals by 12.2% in the 3rd quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock valued at $25,537,000 after purchasing an additional 3,385 shares during the last quarter. LPL Financial LLC grew its stake in shares of Regeneron Pharmaceuticals by 9.3% in the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after purchasing an additional 3,479 shares during the last quarter. Cavalier Investments LLC grew its stake in shares of Regeneron Pharmaceuticals by 88.6% in the 3rd quarter. Cavalier Investments LLC now owns 4,436 shares of the biopharmaceutical company’s stock valued at $3,651,000 after purchasing an additional 2,084 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in shares of Regeneron Pharmaceuticals by 32.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after purchasing an additional 1,221 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity

In other news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold 13,729 shares of company stock worth $13,124,641 over the last quarter. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.3 %

NASDAQ:REGN opened at $966.30 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $998.33. The firm has a market capitalization of $106.06 billion, a PE ratio of 27.81, a price-to-earnings-growth ratio of 2.77 and a beta of 0.11. The stock has a 50 day moving average of $957.54 and a 200-day moving average of $878.93. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same period last year, the company posted $10.96 EPS. The firm’s quarterly revenue was up .6% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.75 EPS for the current year.

Wall Street Analyst Weigh In

REGN has been the subject of several recent analyst reports. Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. TD Cowen raised their price target on Regeneron Pharmaceuticals from $900.00 to $1,000.00 and gave the company an “outperform” rating in a report on Wednesday, December 6th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, January 5th. Truist Financial reaffirmed a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday. Finally, Royal Bank of Canada lifted their price objective on Regeneron Pharmaceuticals from $1,096.00 to $1,184.00 and gave the stock an “outperform” rating in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $967.59.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.